Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States

Overview of attention for article published in Advances in Therapy, August 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 17 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 15 publications that cite this research output.

15

The most recent citing publications are shown below. View all 15 publications that cite this research output on Dimensions.

Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.

Article in JCO Oncology Practice (April 2024)

Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches

Article in Clinical Drug Investigation (January 2024)

Viral Infections and Incidence of Reactivations in Chronic Myeloid Leukemia Patients

Article in Oncology (October 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.